SRC and neoplasm: The combination of SRC‐1 deficiency and PD‐L1 blockade elicited synergistic antitumor effects, manifested in a slower tumor growth, reduced tumor volume and weight compared with SRC‐1 deficiency alone or PD‐L1 antibody monotherapy group (Figure 6A,B).